First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study
<p>Abstract</p> <p>Background</p> <p>This phase II study evaluated the efficacy and safety of gemcitabine (G) plus paclitaxel (T) as first-line therapy in recurrent or metastatic breast cancer.</p> <p>Methods</p> <p>Patients with locally, recurre...
Main Authors: | Piperno-Neumann Sophie, Tubiana-Mathieu Nicole, Tubiana-Hulin Michele, Gawande Sulochana R, Allouache Djelila, Mefti Fawzia, Bozec Laurence, Genot Jean-Yves |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2005-11-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/5/151 |
Similar Items
-
A case of metastatic NUT carcinoma with prolonged response on gemcitabine and nab‐paclitaxel
by: Shetal A. Patel, et al.
Published: (2021-08-01) -
Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
by: Chiorean EG, et al.
Published: (2018-05-01) -
Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck
by: Ammar Sukari, et al.
Published: (2015-04-01) -
Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
by: Ken Kamata, et al.
Published: (2023-09-01) -
Efficacy and safety of albumin-bound paclitaxel combined with gemcitabine in the treatment of advanced and metastatic pancreatic cancer
by: TIAN Yue, et al.
Published: (2023-09-01)